NOTE - Carmat - Acheter vs Suspendue - Obj. 27.10€
La suspension des implantations suite à l'apparition de problèmes de qualité a mis un coup de frein à la dynamique commerciale naissante de Carmat. Nous ajustons nos scénarios pour prendre en compte d'une part le nouveau calendrier et d'autre part un ramp-up plus modéré en lien avec les limites des capacités de production.Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.